Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of six anticancer drugs that have been studied in various combinations, but not as a single six-drug regimen based on available information. The individual components have different mechanisms of action: - Cisplatin: A platinum-based chemotherapy that causes DNA crosslinking - Docetaxel: A taxane that inhibits cell division by disrupting microtubule function - Gefitinib: An EGFR tyrosine kinase inhibitor - Pemetrexed: An antifolate that inhibits multiple enzymes in the folate pathway - Vinorelbine: A vinca alkaloid that disrupts microtubules - Gemcitabine: A nucleoside analog that inhibits DNA synthesis Various combinations of these drugs have been studied for the treatment of non-small-cell lung cancer (NSCLC) and other cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cisplatin + docetaxel + gefitinib + pemetrexed + vinorelbine + gemcitabine.